Sign in
Enrolling by invitationPhase 2

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

Key facts

Who runs it
University of Nebraska
Where
Omaha, United StatesSee the site
Trial code
Status
Enrolling by invitation
Phase
Phase 2
People taking part
100 people, planned
Started
13 Apr 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • isotretinoin
  • Human chorionic gonadotrophin (hCG)
Record updated
20 April 2026

Who can take part

Age
19 years to 50 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Male participants aged 19 to 50 years
  • Confirmed diagnosis of oligospermia (sperm concentration <15 million/mL), nonobstructive azoospermia, or hypogonadotropic hypogonadism (defined by low or normal FSH with low testosterone)
  • Normal genetic evaluation if diagnosed with azoospermia
  • No other identified and correctable cause of infertility
  • Considered appropriate candidates for medical therapy for infertility in the clinical judgment of the investigators
  • Willing and able to comply with study procedures, including laboratory testing, semen analyses, and follow-up visits
  • Able to provide informed consent

Who cannot take part

  • Obstructive azoospermia (including vasal obstruction, ejaculatory duct obstruction, or prior vasectomy)
  • Prior successful medical therapy for infertility
  • Current or recent use of medications known to impair spermatogenesis, including exogenous testosterone or anabolic steroids, unless discontinued with adequate washout
  • Contraindications to isotretinoin (including significant liver disease or uncontrolled hyperlipidemia)
  • Contraindications to human chorionic gonadotropin (including hormone-sensitive malignancy)
  • Significant medical or psychiatric conditions that, in the opinion of the investigators, would interfere with safe participation
  • Current use of isotretinoin for any indication
  • Inability to provide semen samples
  • Inability to provide informed consent

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 50 years old?

Where in United States

  • University of Nebraska Medical CenterOmaha, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study compares two medical treatments to see how well they improve sperm production in men with infertility due to low sperm counts (oligospermia) or no sperm in the semen due to non-obstructive causes (nonobstructive azoospermia). Some men with these conditions have limited nonsurgical treatment options, and current therapies do not work for everyone.

Read full original descriptionShow less

Participants in this study will be adult men ages 19 to 50 who have been diagnosed with oligospermia or nonobstructive azoospermia and do not have a correctable cause for infertility. Eligible participants will be randomly assigned to receive one of two treatments for three months: oral isotretinoin taken twice daily, or human chorionic gonadotropin (hCG) injections given three times per week. hCG is a standard hormonal therapy used in certain types of male infertility, while isotretinoin is being studied for its potential role in stimulating sperm production.

At the start of the study, participants will have blood tests to measure reproductive hormone levels and a semen analysis. Blood tests will be repeated at one month and three months, and a repeat semen analysis will be performed at three months, which corresponds to a full cycle of sperm development. The main goal of the study is to determine whether motile (moving) sperm appear in the semen after treatment. Additional goals include measuring changes in sperm count and hormone levels, as well as monitoring medication side effects.

Both study medications are FDA-approved and have known side effect profiles. Participants may or may not experience improvement in sperm production. The results of this study may help guide future treatment options for men with infertility due to low or absent sperm production.

The 2 groups in the trial

  • Isotretinoin Treatment ArmTreatment being tested

    Participants in this arm will receive oral isotretinoin 20 mg twice daily for 3 months. Reproductive hormone testing will be performed at baseline, 1 month, and 3 months, and a semen analysis will be repeated at 3 months to assess treatment response.

    Treatment: isotretinoin

  • hCG Treatment ArmExisting treatment, for comparison

    Participants in this arm will receive human chorionic gonadotropin (hCG) injections at a dose of 2,000 units three times weekly for 3 months. Reproductive hormone testing will be performed at baseline, 1 month, and 3 months, and a semen analysis will be repeated at 3 months to assess treatment response

    Treatment: Human chorionic gonadotrophin (hCG)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Comparison of Isotretinoin and hCG Therapy in Males With Oligospermia and Azoospermia
Criteria questions
Built from NCT07481370, who can take part
Record updated
20 April 2026